Valuation
- Market cap
- 570,881,000
- Revenue TTM
- $0
- Net income TTM
- $-29,440,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,302,400
- Avg volume
- 1,592,854
- Day's range
- $8.00 – $8.35
- Shares out
- 71,539,000
- Stochastic %K
- 16%
- Beta
- 0.24
- Analysts
- Strong Sell
- Price target
- $24.57
Company profile
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 310 651 8041
- Website
- https://www.immixbio.com
- Address
- 11400 West Olympic Boulevard, Suite 200, Los Angeles, United States
Latest news
No headlines yet.
